BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 29369421)

  • 1. Genetic variation in IL28B (IFNL3) and response to interferon-alpha treatment in myeloproliferative neoplasms.
    Lindgren M; Samuelsson J; Nilsson L; Knutsen H; Ghanima W; Westin J; Johansson PL; Andréasson B
    Eur J Haematol; 2018 May; 100(5):419-425. PubMed ID: 29369421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients.
    Zhang Q; Lapalus M; Asselah T; Laouénan C; Moucari R; Martinot-Peignoux M; Bieche I; Estrabaud E; De Muynck S; Boyer N; Bedossa P; Vidaud M; Marcellin P; Lada O
    J Viral Hepat; 2014 Jul; 21(7):525-32. PubMed ID: 24118626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.
    Moghaddam A; Melum E; Reinton N; Ring-Larsen H; Verbaan H; Bjøro K; Dalgard O
    Hepatology; 2011 Mar; 53(3):746-54. PubMed ID: 21374656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
    Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
    Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
    Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.
    Sonneveld MJ; Wong VW; Woltman AM; Wong GL; Cakaloglu Y; Zeuzem S; Buster EH; Uitterlinden AG; Hansen BE; Chan HL; Janssen HL
    Gastroenterology; 2012 Mar; 142(3):513-520.e1. PubMed ID: 22108195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms.
    Mondello P; Di Mirto C; Cuzzocrea S; Arrigo C; Mian M; Pitini V
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e489-e495. PubMed ID: 31231012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.
    Boglione L; Cusato J; Allegra S; Cariti G; Di Perri G; D'Avolio A
    Arch Virol; 2015 Aug; 160(8):2009-17. PubMed ID: 26060059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms.
    Hansen IO; Sørensen AL; Hasselbalch HC
    Eur J Haematol; 2017 Jan; 98(1):75-84. PubMed ID: 27471124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection.
    Lange CM; Moradpour D; Doehring A; Lehr HA; Müllhaupt B; Bibert S; Bochud PY; Antonino AT; Pascual M; Farnik H; Shi Y; Bechstein WO; Moench C; Hansmann ML; Sarrazin C; Lötsch J; Zeuzem S; Hofmann WP
    J Hepatol; 2011 Aug; 55(2):322-7. PubMed ID: 21147186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.
    Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
    PLoS One; 2015; 10(9):e0137365. PubMed ID: 26339796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms in the IL28B gene (rs12979860, rs8099917) and the virological response to pegylated interferon therapy in hepatitis D virus patients.
    Yilmaz B; Can G; Ucmak F; Arslan AO; Solmaz I; Unlu O; Düzenli S; Korkmaz U; Kurt M; Senates E
    Acta Gastroenterol Belg; 2016; 79(2):206-10. PubMed ID: 27382939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL28B rs12980275 polymorphism shows association with response to treatment in Pakistani patients with chronic hepatitis C.
    Shaikh N; Waryah AM; Devrajani BR; Rajput MI; Hayat AS; Shaikh S
    J Med Virol; 2015 May; 87(5):814-20. PubMed ID: 25652367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High resolution melting curve assay for detecting rs12979860 IL28B polymorphisms involved in response of Iranian patients to chronic hepatitis C treatment.
    Fateh A; Aghasadeghi MR; Keyvani H; Mollaie HR; Yari S; Hadizade Tasbiti AR; Ghazanfari M; Monavari SH
    Asian Pac J Cancer Prev; 2015; 16(5):1873-80. PubMed ID: 25773839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL28B polymorphism cannot predict response to interferon alpha treatment in patients with melanoma.
    Probst M; Hoeller C; Ferenci P; Staettermayer AF; Beinhardt S; Pehamberger H; Kittler H; Grabmeier-Pfistershammer K
    PLoS One; 2014; 9(11):e112613. PubMed ID: 25389973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
    Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
    Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin- 28B: a prognostic marker in interferon based therapy of chronic HCV patients of the Pakistan with variable treatment response.
    Resham S; Manzoor S; Imran M; Saalim M; Naseem S; Azam S
    APMIS; 2015 Sep; 123(9):765-71. PubMed ID: 26177560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
    Susser S; Herrmann E; Lange C; Hamdi N; Müller T; Berg T; Perner D; Zeuzem S; Sarrazin C
    PLoS One; 2014; 9(11):e112592. PubMed ID: 25393304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection.
    Chang KC; Tseng PL; Wu YY; Hung HC; Huang CM; Lu SN; Wang JH; Lee CM; Chen CH; Tsai MC; Yen YH; Lin MT; Wu CK; Huang CC; Chen HH; Hu TH
    Clin Gastroenterol Hepatol; 2015 May; 13(5):1017-24. PubMed ID: 25460552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.